Zai Lab Ltd（ZLAB）股票分析ZLABZai Lab Ltd

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zai Lab Ltd is a good buy right now due to its recent positive clinical trial results showing an 81.8% objective response rate and a significant financing announcement of $250 million at $22.04 per share. The current price of $24.03 is below the analyst price targets of $36 and $45, indicating substantial upside potential. However, the company is facing challenges with a negative net income of -$51 million in Q2 2026, which poses a risk for investors.

3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.